{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T11:34:48Z","timestamp":1776425688791,"version":"3.51.2"},"reference-count":23,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,7,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Mantle cell lymphoma (MCL) generally exhibits an aggressive disease course with poor outcomes. Despite inherent radiosensitivity, radiation therapy (RT) is not commonly used for MCL. This study assesses the role of low-dose RT (LDRT) with concurrent chemotherapy in relapsed, multiply refractory MCL. From 2014 through 2018, 19 patients with relapsed, refractory MCL had 98 sites treated with 4 Gy. Median follow-up from initial LDRT was 15.4 months. Patients had received a median 7 courses of chemotherapy since diagnosis, and 58% were ibrutinib-refractory. Of the 98 sites, 76% were refractory to ongoing chemotherapy, and LDRT was delivered with concurrent chemotherapy for 76%. The complete response (CR) rate was 81% at a median 2.7 months post-LDRT. There were no differences in CR despite ibrutinib-refractory disease, prior chemotherapy courses (&amp;gt;5), or tumor size (&amp;gt;3 cm). There were no RT-related toxicities. Overall survival at 1 year following initial LDRT was 90%, and 1-year progression-free survival following last course was 55%. In summary, LDRT is effective for relapsed, multiply refractory MCL, and may be safely delivered with chemotherapy, to multiple sites, and repeatedly without issue. By treating active sites of disease, LDRT can provide durable local control, help achieve remission, and potentially bridge patients to subsequent novel therapies.<\/jats:p>","DOI":"10.1182\/bloodadvances.2019030858","type":"journal-article","created":{"date-parts":[[2019,7,9]],"date-time":"2019-07-09T16:54:01Z","timestamp":1562691241000},"page":"2035-2039","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":20,"title":["Low-dose radiation (4 Gy) with\/without concurrent chemotherapy is highly effective for relapsed, refractory mantle cell lymphoma"],"prefix":"10.1182","volume":"3","author":[{"given":"Matthew S.","family":"Ning","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chelsea C.","family":"Pinnix","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhavana V.","family":"Chapman","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jillian R.","family":"Gunther","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah A.","family":"Milgrom","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2621-3584","authenticated-orcid":false,"given":"Joseph D.","family":"Khoury","sequence":"additional","affiliation":[{"name":"Department of Hematopathology, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Preetesh","family":"Jain","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy Y.","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Onyeka N.","family":"Oriabure","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria R.","family":"Badillo","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9748-5486","authenticated-orcid":false,"given":"L. Michael","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bouthaina S.","family":"Dabaja","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology,"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2019,7,9]]},"reference":[{"issue":"11","key":"2020021108161738200_B1","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1200\/JCO.2015.63.5904","article-title":"Mantle cell lymphoma","volume":"34","author":"Cheah","year":"2016","journal-title":"J Clin Oncol"},{"issue":"29","key":"2020021108161738200_B2","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1200\/JCO.2013.49.2835","article-title":"Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study","volume":"31","author":"Goy","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"2020021108161738200_B3","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/annonc\/mdn656","article-title":"Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study","volume":"20","author":"Goy","year":"2009","journal-title":"Ann Oncol"},{"issue":"7","key":"2020021108161738200_B4","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.3324\/haematol.2011.041392","article-title":"Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma","volume":"96","author":"Lamm","year":"2011","journal-title":"Haematologica"},{"issue":"11","key":"2020021108161738200_B5","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1093\/annonc\/mdt366","article-title":"Long-term follow-up of lenalidomide in relapsed\/refractory mantle cell lymphoma: subset analysis of the NHL-003 study","volume":"24","author":"Zinzani","year":"2013","journal-title":"Ann Oncol"},{"issue":"1","key":"2020021108161738200_B6","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(15)00438-6","article-title":"Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial","volume":"17","author":"Wang","year":"2016","journal-title":"Lancet Oncol"},{"issue":"6","key":"2020021108161738200_B7","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"issue":"10121","key":"2020021108161738200_B8","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(17)33108-2","article-title":"Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial","volume":"391","author":"Wang","year":"2018","journal-title":"Lancet"},{"issue":"3","key":"2020021108161738200_B9","doi-asserted-by":"crossref","first-page":"416","DOI":"10.3324\/haematol.2011.051813","article-title":"Salvage treatment with lenalidomide and dexamethasone in relapsed\/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers","volume":"97","author":"Zaja","year":"2012","journal-title":"Haematologica"},{"issue":"7","key":"2020021108161738200_B10","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S1470-2045(12)70200-0","article-title":"Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1\/2 clinical trial","volume":"13","author":"Wang","year":"2012","journal-title":"Lancet Oncol"},{"issue":"12","key":"2020021108161738200_B11","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1182\/blood-2015-10-673145","article-title":"Postibrutinib outcomes in patients with mantle cell lymphoma","volume":"127","author":"Martin","year":"2016","journal-title":"Blood"},{"issue":"6","key":"2020021108161738200_B12","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1093\/annonc\/mdv111","article-title":"Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes","volume":"26","author":"Cheah","year":"2015","journal-title":"Ann Oncol"},{"issue":"4","key":"2020021108161738200_B13","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/bjh.15567","article-title":"Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib","volume":"183","author":"Jain","year":"2018","journal-title":"Br J Haematol"},{"issue":"9","key":"2020021108161738200_B14","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1093\/annonc\/mdx334","article-title":"Early-stage mantle cell lymphoma: a retrospective analysis from the International Lymphoma Radiation Oncology Group (ILROG)","volume":"28","author":"Dabaja","year":"2017","journal-title":"Ann Oncol"},{"issue":"5","key":"2020021108161738200_B15","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/1754-9485.12335","article-title":"Involved-field radiotherapy for patients with mantle cell lymphoma","volume":"59","author":"Neville","year":"2015","journal-title":"J Med Imaging Radiat Oncol"},{"issue":"4","key":"2020021108161738200_B16","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.ijrobp.2006.02.011","article-title":"Highly effective local control and palliation of mantle cell lymphoma with involved-field radiation therapy (IFRT)","volume":"65","author":"Rosenbluth","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"2020021108161738200_B17","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.clml.2014.07.003","article-title":"Radiation therapy is an effective modality in the treatment of mantle cell lymphoma, even in heavily pretreated patients","volume":"14","author":"Haque","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"2020021108161738200_B18","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ijrobp.2012.12.024","article-title":"Low-dose involved-field radiation in the treatment of non-Hodgkin lymphoma: predictors of response and treatment failure","volume":"86","author":"Russo","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"2020021108161738200_B19","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1440-1673.2006.01566.x","article-title":"Value of low-dose 2 x 2 Gy palliative radiotherapy in advanced low-grade non-Hodgkin\u2019s lymphoma","volume":"50","author":"Ng","year":"2006","journal-title":"Australas Radiol"},{"issue":"9","key":"2020021108161738200_B20","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.3109\/10428194.2015.1131274","article-title":"2 Gy\u2009\u00d7\u20092 for palliative treatment of mantle cell lymphoma","volume":"57","author":"White","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2020021108161738200_B21","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ijrobp.2014.01.006","article-title":"Modern radiation therapy for nodal non-Hodgkin lymphoma-target definition and dose guidelines from the International Lymphoma Radiation Oncology Group","volume":"89","author":"Illidge","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"2020021108161738200_B22","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijrobp.2015.01.009","article-title":"Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group","volume":"92","author":"Yahalom","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"2020021108161738200_B23","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/13\/2035\/1631982\/advances030858.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/13\/2035\/1631982\/advances030858.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T08:20:34Z","timestamp":1581409234000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/3\/13\/2035\/246604\/Lowdose-radiation-4-Gy-withwithout-concurrent"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,9]]},"references-count":23,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2019,7,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2019030858","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,9]]}}}